Testing the Addition of an Immunotherapy Agent, Atezolizumab, When Given With the Usual Chemo-Immunotherapy Drug Combination (Rituximab Plus Gemcitabine and Oxaliplatin) for Relapsed/Refractory (That Has Come Back or Not Responded to Treatment) Transformed Diffuse Large B-Cell Lymphoma

Clinical trial NCT03321643 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT03321643
Sponsor: National Cancer Institute (NCI)
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Recurrent Diffuse Large B-Cell Lymphoma Recurrent Transformed Non-Hodgkin Lymphoma Refractory Diffuse Large B-Cell Lymphoma Refractory Transformed Non-Hodgkin Lymphoma Richter Syndrome Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma

Start date: 2018-09-18
Primary completion: 2027-06-30
Enrollment: 24

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.